On Monday, October 27 2025, NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced the signing of a Memorandum of Understanding with TargetGene Biotechnologies Ltd. to advance next‑generation gene‑edited cell therapies. The agreement will be executed under the combined company NewCelX, following the completion of the anticipated merger between NLS and Kadimastem.
TargetGene is a pioneer in precision gene‑editing technologies, and the partnership is intended to accelerate the development of cell‑based treatments for severe diseases such as amyotrophic lateral sclerosis (ALS) and type 1 diabetes. By combining Kadimastem’s all‑ogeneic cell therapy platform with TargetGene’s gene‑editing expertise, the collaboration aims to create more effective, off‑the‑shelf therapeutic candidates.
Strategically, the MOU expands NewCelX’s portfolio beyond its existing CNS pipeline, positioning the company to pursue multiple therapeutic modalities and potentially generate new revenue streams. The partnership underscores the company’s commitment to diversifying its product development and leveraging complementary technologies to enhance its competitive standing in the biopharmaceutical market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.